Traws Pharma (TRAW) Accounts Payables (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Accounts Payables of $7.7 million for Q1 2026, little changed year-over-year from $7.7 million in Q1 2025, and up 35.59% quarter-over-quarter from $5.7 million in Q4 2025.
Traws Pharma (TRAW) Accounts Payables (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Accounts Payables for 15 consecutive years, with $7.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables changed 0.12% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (changed 0.12% YoY), while the FY2025 annual figure was $5.7 million, down 30.94% from the prior year.
- Accounts Payables advanced to $7.7 million in Q1 2026 per TRAW's latest filing, from $5.7 million in the prior quarter.
- Across five years, Accounts Payables topped out at $8.2 million in Q4 2024 and bottomed at $3.0 million in Q2 2022.
- Historically, Accounts Payables has averaged $5.5 million across 5 years, with a median of $5.5 million in 2024.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 68.86% — and 2025, when it slumped 30.94%.
- Traws Pharma's Accounts Payables stood at $3.9 million in 2022, then surged by 45.57% to $5.6 million in 2023, then jumped by 45.68% to $8.2 million in 2024, then plunged by 30.94% to $5.7 million in 2025, then soared by 35.59% to $7.7 million in 2026.
- Business Quant data shows TRAW's Accounts Payables at $7.7 million in Q1 2026, $5.7 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 35.57 Mn |
| 10 | Traws Pharma | 5.64 Mn | 623,530.95 | - | 6.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.67 Mn |
| Dec 31, 2025 | 5.65 Mn |
| Sep 30, 2025 | 5.11 Mn |
| Jun 30, 2025 | 4.76 Mn |
| Mar 31, 2025 | 7.66 Mn |
| Dec 31, 2024 | 8.19 Mn |
| Sep 30, 2024 | 5.47 Mn |
| Jun 30, 2024 | 6.17 Mn |
| Mar 31, 2024 | 6.57 Mn |
| Dec 31, 2023 | 5.62 Mn |
| Sep 30, 2023 | 6.15 Mn |
| Jun 30, 2023 | 5.07 Mn |
| Mar 31, 2023 | 4.90 Mn |
| Dec 31, 2022 | 3.86 Mn |
| Sep 30, 2022 | 3.76 Mn |
| Jun 30, 2022 | 3.00 Mn |
| Mar 31, 2022 | 3.12 Mn |
| Dec 31, 2021 | 2.76 Mn |
| Sep 30, 2021 | 4.05 Mn |
| Jun 30, 2021 | 4.29 Mn |